To examine the effect of interventions to optimize medication use on adverse drug reactions (ADRs) in older adults. DESIGN: Systematic review and meta-analysis. EMBASE, PubMed, OVID, Cochrane Library, Clinicaltrials.gov, and Google Scholar were searched through April 30, 2017. SETTING: Randomized controlled trials. PARTICIPANTS: Older adults (mean age ≥65) taking medications. MEASUREMENTS: Two authors independently extracted relevant information and assessed studies for risk of bias. Discrepancies were resolved in consensus meetings. The outcomes were any and serious ADRs. Random-effects models were used to combine the results of multiple studies and create summary estimates. RESULTS: Thirteen randomized controlled trials involving 6,198 older adults were included. The studies employed a number of different interventions that were categorized as pharmacist-led interventions (8 studies), other health professional-led interventions (3 studies), a brief educational session (1 study), and a technology intervention (1 study). The intervention group was 21% less likely than the control group to experience any ADR (odds ratio (OR) = 0.79, 95% confidence interval (CI) = 0.62-0.99). In the six studies that examined serious ADRs, the intervention group was 36% less likely than the control group to experience a serious ADR (OR = 0.64, 95% CI = 0.42-0.98). CONCLUSION: Interventions designed to optimize medication use reduced the risk of any and serious ADRs in older adults. Implementation of these successful interventions in healthcare systems may improve medication safety in older adults. J Am Geriatr Soc 66:282-288, 2018.
A dverse drug events (ADEs), defined as "an injury due to a medication," are a major public health problem for older adults. 1 Adverse drug reactions (ADRs), the most common subset of ADEs, are defined as "a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function" and excludes therapeutic failure and adverse drug withdrawal events. 2, 3 A recent metaanalysis determined that nearly 9% of hospital admissions are due to ADRs in older adults. 4 Moreover, ADRs occur frequently in community-dwelling older adults (10-35% yearly), especially during transitions from higher levels of care such as after hospital discharge. 5, 6 Polypharmacy is a consistent risk factor for ADRs. 7 Inappropriate prescribing and monitoring of medications further predispose older adults to ADRs. 8, 9 Prevention of ADRs in older adults is necessary because they worsen quality of life and increase healthcare system costs. Further evidence of their importance is the current federal initiative focused on ADR prevention efforts for the high-risk medication classes of anticoagulants, diabetes agents, and opioids. 10 However, there is a
From the a Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington; b gap in the current literature regarding the effect that rigorously designed intervention studies have on reducing ADRs in older adults. A recent Cochrane review examined the effect of various interventions on inappropriate polypharmacy in older adults, but only 3 of the 12 included studies measured ADRs as secondary outcomes, which precluded conducting a meta-analysis. 11 A group from Ireland recently published two separate meta-analyses of the effect of pharmacist interventions on prescribing quality in older adults. 12, 13 One focused on 5 studies conducted in primary care, but only one study examined ADRs as a secondary outcome. 12 The second focused on 4 interventions conducted in the inpatient setting, of which only two studies examined ADRs as a secondary outcome. 13 Only one meta-analysis in which ADRs were the primary outcome has been published.
14 It was limited in that none of the 6 included studies used a randomized controlled design, only one type of intervention was examined (in-hospital computerized order entry), and the effect in older adults was not examined.
Given this background, the objective of the current study was to examine the effect of interventions to optimize medication use on ADRs in older adults.
METHODS

Search Strategy
To identify relevant studies, we performed a systematic review of the literature using EMBASE, PubMed, OVID, Cochrane Library, Clinicaltrials.gov, and Google Scholar through April 30, 2017 . The search terms included a combination of the following key words: aged, adverse drug events or reaction, randomized controlled trials, and English language. Table S1 provides an example of the EMBASE database search strategy used. We also examined the citations from seminal studies, reviews, book chapters, and the authors' own files.
Study Selection
Two reviewers (SLG, JTH) examined the titles and then the abstracts of studies to identify those using unifaceted or multifaceted interventions aimed at reducing medication errors in any setting. We also examined the full manuscripts for these studies and included only those in which the average age of participants was 65 and older, that used a randomized controlled trial design, and that measured ADRs as a primary outcome or as part of an overall assessment of drug-related problems.
Data Extraction
Two of the authors (SLG, JTH) created a standardized data collection form based in part on the PRISMA guidelines that was piloted and revised with input from the biostatistician, two other research pharmacists (LAH, TPS), and a geriatrician (KES). 15, 16 Elements of the final data collection form included author name, date of publication, country, sample size, mean age of each study arm, setting (e.g., nursing home), study intervention type (e.g., pharmacist-led), follow-up time, and rate of any and serious ADRs according to group status. Details about ADR assessment included process for detecting ADRs (e.g., chart review, patient interview), method for assessing causality (e.g., whether a formal causality algorithm was used 17 ), and number and background of the evaluators. Two reviewers independently extracted study data (SLG, JTH). Discrepancies were resolved in consensus meetings. Because published studies used the terms ADE and ADR interchangeably, when necessary for clarification, the authors of the primary studies were contacted to ensure that the study outcome of interest for this meta-analysis, ADRs, were addressed.
Assessment of Study Quality
Two authors (SLG, LAH) independently assessed the methodological quality of the studies using the Cochrane Collaboration tool for assessing risk of bias. 18 The domains considered addressed selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), and reporting bias (selective reporting). Discrepancies were resolved in consensus meetings.
Outcomes
Any ADR was the primary outcome for this meta-analysis. 2, 3 The secondary outcome was rate of serious ADRs, defined as those associated with death, hospitalization, prolonged hospitalization, permanent disability, or need for an intervention to prevent permanent impairment. 19 
Statistical Analysis
The incidence of ADRs was presented in different formats for the individual studies, including number of participants, number of events, proportions, and rates per person time. Before analysis, we converted all ADR information from the studies to estimate the numbers of persons experiencing an ADR out of the total numbers of persons exposed, assuming a Poisson distribution for the events. Odds ratios (ORs) were computed for each study, representing the intervention versus control group difference. We fitted fixed-effects models for combining the log ORs from the studies and used the Cochran Q-statistic and Higgins I 2 statistic for assessing the extent of heterogeneity. 20 Generally, an I 2 of 25% is considered to be low, 50% moderate, and 75% high heterogeneity. Upon observing a high level of heterogeneity, we used a random-effects model to pool the individual log ORs and obtain an overall estimate that incorporates between-study heterogeneity. 21 We performed a series of leave-one-out-at-a-time meta-analyses to identify the most influential studies, a cumulative meta-analysis to examine the accumulation of evidence over time, and a post-hoc analysis that was restricted to studies of pharmacist-led interventions. We constructed forest plots to present the results graphically and created a funnel plot and performed Egger's test to examine possible publication bias. 22 Because serious ADRs were sufficiently rare, we assumed that exposed persons would at most have one event and repeated the above analysis. Comprehensive Meta-Analysis version 2 (Biostat, Inc., Englewood, NJ) was used for all analyses.
RESULTS
Characteristics of Included Studies
Of the 10,176 citations retrieved, 13 studies involving 6,198 participants were eligible for inclusion in this review ( Figure 1 ). Three study authors provided specific requested raw data to allow for their study inclusion. The study characteristics are presented in Table 1 . The studies were conducted in Europe (7 studies), [23] [24] [25] [26] [27] [28] [29] North America (5 studies), 19, [30] [31] [32] [33] 29 Two studies evaluated the effects of inpatient pharmacist-led interventions on outcomes after hospital discharge. 23, 28 Total follow-up time ranged from 2 to 12 months for studies that examined ADRs in nonhospital settings. 19, 23, [27] [28] [29] [30] [31] [32] [33] [34] The most common type of intervention was pharmacist-led (8 studies) with a core component of medication review that involved a number of implicit structured methods to identify drug-related problems 23, 27, 28, 30, 31, 34 or a combination of explicit and implicit approaches. 25, 29 One study used clinical decision support software to support the pharmacists' medication review process. 25 Different modes of communication were used to relay recommendations to the prescriber. In most studies, the recommendations were made in person to the prescriber, 23, [28] [29] [30] 34 but other studies primarily communicated recommendations through the medical record or facsimile. 25, 27, 31 Pharmacists also provided education directly to participants in some studies. 23, 27, 28, 30, 31 Five studies used other interventions to optimize medication use to reduce ADRs: other health professional-led interventions, 19, 24, 32 use of clinical decision support added to computerized order entry, 33 and a one-time educational session for physicians. 26 Eleven studies used interventions to improve overall prescribing rather than focusing specifically on reducing ADRs, and one study focused on improving safety of warfarin. 32 Details of the interventions are provided in Table S2 .
Most studies used medical record review to detect potential ADRs, 19, [23] [24] [25] [26] 28, 29, [32] [33] [34] with only 2 studies using more than 1 method. 19, 28 Some studies used rigorous assessment of ADRs as determined by using 2 or more reviewers 19, 23, 25, 26, 29, 32, 33 and/or an ADR causality algorithm. 19, 24, 25, 31 Methodological Quality of Studies Assessment of the risk of bias is summarized in Table S3 . All studies were at high risk of performance bias because personnel, participants, or both could not be blinded because of the nature of the intervention, and thus this domain was not reported. Most studies had low risk of detection bias. The allocation concealment was unclear for 10 studies. 19, [24] [25] [26] [27] [28] [29] [30] [31] 33 Outcomes Of the 13 studies included in the metaanalysis, 2 reported outcomes for 2 interventions.
19,31 Thus, 15 interventions were included in the meta-analysis. Upon observing substantial heterogeneity for the outcome of any ADR (I 2 = 72.8%), we used a random-effects model. Participants randomized to the intervention group were 21% less likely to experience an ADR than those in the control group (OR = 0.79, 95% confidence interval (CI) = 0.62-0.99; Figure 2 ). When the analysis was restricted to pharmacist-led interventions, the intervention group was 35% less likely to experience an ADR relative With all 15 intervention arms, the Egger test for publication bias was statistically significant (P = .04) ( Figure S1 ). One-at-a-time removal of studies from the meta-analysis did not materially change the pooled OR, but one study was the most influential (data not shown). 23 Over time, the cumulative meta-analysis showed that the accumulating evidence started favoring interventions around 2009 according to magnitude and around 2016 according to statistical significance (data not shown). Six studies examined the outcome of serious ADRs. 19, [23] [24] [25] 32, 33 There was substantial heterogeneity (I 2 = 80.8%) for serious ADRs. From a random-effects model, participants who received the intervention were 36% less likely to experience a serious ADR (OR = 0.64, 95% CI = 0.42-0.98; Figure 3 ) than controls. Forest plot of intervention effects on likelihood of experiencing any adverse drug reaction. Pooled estimates (diamond) calculated using random-effects model for pooling individual log odds ratios and obtaining an overall estimate that incorporates between-study heterogeneity. Figure 3 . Forest plot of intervention effects on likelihood of experiencing a serious adverse drug reaction. Pooled estimates (diamond) calculated using random-effects model for pooling individual log odds ratios and obtaining an overall estimate that incorporates between-study heterogeneity.
DISCUSSION
To the best of our knowledge, this is the first meta-analysis to examine the effectiveness of interventions to reduce ADRs in older adults. We identified 13 studies evaluating 15 intervention arms to include in the meta-analysis. Three previous meta-analyses on interventions to improve prescribing and health outcomes in older adults found only 4 unique studies that evaluated ADRs. [12] [13] [14] Interventions to optimize medication use were associated with lower risk of ADRs compared to usual care. Based on the point estimates, there was clear evidence that the intervention was effective in reducing ADRs for 8 of the 15 study arms, whereas 1 intervention arm had a point estimate suggesting greater risk of ADRs. Furthermore, we observed significantly fewer serious ADRs. Based on the point estimates, there was clear evidence that the intervention was effective in reducing serious ADRs for 5 of the 6 study arms, whereas 1 intervention arm had a point estimate suggesting greater risk of serious ADRs. Evaluating serious ADRs is important, as shown in a study in which the intervention reduced serious ADRs but not any ADRs. 32 These findings have important implications because ADR prevention is a national priority for improving safety. 10 This review demonstrates that a variety of interventions were successful in reducing the risk of any ADRs. Most studies used a pharmacist-led intervention, and in these studies, we found a 35% reduction in odds of ADRs. ADRs, although even in these studies, the interventions varied considerably with regard to intensity, mode of communication with providers, provision of patient education, and setting. For example, one study evaluated a comprehensive intervention using a pharmacist integrated into the ward team to optimize medication use throughout the hospitalization and provide discharge counselling and a follow-up telephone call 2 months after discharge. 23 In contrast, another study evaluated a less-intensive intervention in primary care that involved a medication review before a scheduled physician appointment, with recommendations entered into the medical chart and provided to the patient. 27 Only one study compared two different intensities of interventions with usual care and found that only a high-intensity intervention was effective. 31 Another study found significantly fewer ADRs (absolute risk reduction of 6.8%) with an intervention that used clinical decision support software to assist the pharmacist in identifying potential drug-related problems in hospitalized individuals. 25 Further studies are warranted to determine whether technology can assist with reducing ADRs. We were unable to separately examine the effectiveness of other types of interventions (e.g., other health professional-led interventions) in reducing ADRs because of the small number of studies.
Like any meta-analysis, the present analysis has potential limitations. We found a statistically significant publication bias, which nonpublication of small negative studies probably caused, as commonly observed in meta-analyses. It is possible that we missed non-English language randomized controlled intervention trials. Bias may have been introduced through the data abstraction and evaluation process. To reduce this possibility, we used a standardized abstraction form that the research team approved and piloted before use in the study. Moreover, we used two reviewers, and disagreements were discussed and resolved in a consensus meeting. Regarding generalizability, there were too few studies to conduct analyses specific to type of healthcare setting or country. Most studies were conducted at a single center, so it is unclear how easily the interventions can be replicated in other healthcare systems. Finally, we had to use several reasonable strategies for harmonizing the effects reported using different scales in different studies. However, these are common limitations in meta-analyses and are not particularly unique to ours.
Despite these potential limitations, we conclude that interventions designed to optimize medication use reduce the risk of any and serious ADRs in older adults. Successful implementation of these interventions in healthcare systems may improve medication safety in older adults. Research is needed to identify which interventions and components thereof may be most cost effective for implementation in specific practice settings. Questions remain regarding how best to disseminate these models and provide optimal integration into varied healthcare systems. Completion of planned and on-going studies in primary care (Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in elderly populations by electronic Decision Support) 35 and hospital settings (Software ENgine for the Assessment & optimization of drug and non-drug Therapy in Older peRsons and OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People trials) 36 may answer some of these questions.
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